Nicotine Oral Pouch
Phase 3Small molecule
Nicotine Oral Pouch is one of 42 small molecule programs targeting Concentration. It is currently in Phase 3.
3
Indications
6
Total Trials
4
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
50 competitors in Oral
#DrugCompanyPhaseTrials
1Vepesid
AAvyxa
Phase 2
Marinol
Jazz PharmaceuticalsPhase 1
Nicotine Oral Pouch
OOhio State University Comprehensive Cancer Center
Phase 3
GTX-104
GGrace Therapeutics Inc.
Phase 3
SHR-3167
JJiangsu HengRui Medicine Co., Ltd.
Phase 2
Pitressin
AAultman Health Foundation
Preclinical
Nubain
AAultman Health Foundation
Preclinical
VX-407
Vertex PharmaceuticalsPhase 1
DRSP/EE
Vertex PharmaceuticalsPhase 1
AB-101
AArtiva Biotherapeutics, Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
PPA2 trials
Tobacco-Related Carcinoma2 trials
Concentration1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nicotine Oral Pouch. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details